02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
23:26 , Jun 20, 2019 |  BC Extra  |  Financial News

New listings push IPO pace ahead of last year’s

A spate of biotech IPOs this week in which five companies raised nearly $620 million helped push the biopharma sector’s total haul from NASDAQ listings ahead of 2018’s record pace. Of the five to price...
22:47 , Jun 10, 2019 |  BC Extra  |  Financial News

June 10 Financial Quick Takes: Vivo raises $1.3B for ninth fund; plus Prevail, Dermavant, Akero set terms for IPOs

Vivo has at least $1.3B for next fund  Vivo Capital has raised $1.3 billion toward its ninth fund from 36 investors, according to an SEC filing . The healthcare investment firm did not disclose in...
00:29 , May 25, 2019 |  BC Extra  |  Financial News

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

In a week in which two biotechs went public and a third opted for a billion-dollar takeout instead of an IPO, five companies filed on Friday to list on NASDAQ in IPOs that could raise...
21:19 , May 17, 2019 |  BioCentury  |  Emerging Company Profile

89bio: standing out in the NASH crowd

89bio thinks it can differentiate itself from companies targeting NASH as an inflammatory and fibrotic disease by attacking it as a metabolic disorder and addressing its root cause with an FGF analog that could be...
22:41 , May 2, 2019 |  BC Extra  |  Company News

Management tracks: Akero, NIH, Arcus

Metabolic disease company Akero Therapeutics Inc. (South San Francisco, Calif.) hired Bill White as its first CFO and head of corporate development. He was a managing director and head of U.S. life sciences investment banking...
04:00 , Jan 4, 2019 |  BC Week In Review  |  Financial News

New $250M Atlas fund to target later-stage investments

Atlas Venture closed on Jan. 2 its oversubscribed Atlas Venture Opportunity Fund I at $250 million, intended to support growth for Akero Therapeutics Inc. (South San Francisco, Calif.) and other existing portfolio companies. Atlas told...
18:19 , Jan 2, 2019 |  BC Extra  |  Financial News

New $250M Atlas fund to target later-stage investments

Atlas Venture closed its oversubscribed Atlas Venture Opportunity Fund I at $250 million, intended to support growth for Akero Therapeutics Inc. (South San Francisco, Calif.) and other existing portfolio companies. Atlas told BioCentury the fund...
19:11 , Dec 14, 2018 |  BC Week In Review  |  Financial News

NASH company Akero raises $70M, plans Phase IIa trial

Akero Therapeutics Inc. (San Francisco, Calif.) raised $70 million in a series B round to move non-alcoholic steatohepatitis compound AKR-001 into a Phase IIa trial in mid-2019. The round was led by Janus Henderson Investors...
18:27 , Dec 12, 2018 |  BC Extra  |  Financial News

NASH company Akero raises $70M, plans Phase IIa trial

Akero Therapeutics Inc. (San Francisco, Calif.) raised $70 million in a series B round to move non-alcoholic steatohepatitis compound AKR-001 into a Phase IIa trial in mid-2019. The round was led by Janus Henderson Investors...